Literature DB >> 10715372

Study of the vaginal tolerance to Acidform, an acid-buffering, bioadhesive gel.

E Amaral1, A Faúndes, L Zaneveld, D Waller, S Garg.   

Abstract

Vaginal tolerance tests were performed with a new potential microbicidal and spermicidal product, an acid-buffering vaginal gel (Acidform) without or with nonoxynol-9 (N-9). The potential advantages over other vaginal products include keeping a low pH, decrease of the irritating effect of N-9 on the cervix or vaginal mucosa associated with greater retention of the product after application, and decreasing "messiness" as compared to other vaginal products. Three groups of six women were admitted and randomly assigned to use Acidform with 0%, 2.5%, and 5% N-9. Colposcopic evaluation for vulvar, vaginal, and cervical signs of irritation was performed and photographs were taken, following a specific World Health Organization protocol, at time 0, and after 24 h and 6 days of application of the gel. No irritation or symptom was reported by users of Acidform without N-9. A generalized and intense erythema in cervix was observed in 10 of 12 Acidform/N-9 users and abrasion occurred in nine of them. Vulvar irritation was seen in seven of these 10 volunteers. N-9 concentration in the gel (2.5% or 5.0%) was not related to the findings. No ulcer, exulceration, or de-epithelialization was observed. Acidform without N-9 was well tolerated by volunteers, but it was unable to protect the cervix, vagina, and vulva from the N-9 effects.

Entities:  

Keywords:  Americas; Biology; Brazil; Cervical Effects; Cervix; Clinical Research; Contraception; Contraceptive Agents; Contraceptive Methods; Developing Countries; Diseases; Family Planning; Genitalia; Genitalia, Female; Infections; Latin America; Nonoxynol-9; Physiology; Reproductive Tract Infections; Research Methodology; Research Report; Sexually Transmitted Diseases--prevention and control; South America; Spermicidal Contraceptive Agents; Urogenital System; Uterus; Vaginal Jelly; Vaginal Spermicides

Mesh:

Substances:

Year:  1999        PMID: 10715372     DOI: 10.1016/s0010-7824(99)00102-x

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  13 in total

1.  A pilot clinical trial comparing an acid-buffering formulation (ACIDFORM gel) with metronidazole gel for the treatment of symptomatic bacterial vaginosis.

Authors:  Jose A Simoes; Luis G Bahamondes; Rodrigo P S Camargo; Valeria M N Alves; Lourens J D Zaneveld; Donald P Waller; Jill Schwartz; Marianne M Callahan; Christine K Mauck
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

Review 2.  Non-specific microbicide product development: then and now.

Authors:  Joseph W Romano; Melissa Robbiani; Gustavo F Doncel; Thomas Moench
Journal:  Curr HIV Res       Date:  2012-01-01       Impact factor: 1.581

3.  Neutron-activatable needles for radionuclide therapy of solid tumors.

Authors:  Junghyun Kim; Roger J Narayan; Xiuling Lu; Michael Jay
Journal:  J Biomed Mater Res A       Date:  2017-09-15       Impact factor: 4.396

Review 4.  Vaginal microbicides and the prevention of HIV transmission.

Authors:  Blayne Cutler; Jessica Justman
Journal:  Lancet Infect Dis       Date:  2008-11       Impact factor: 25.071

5.  Vaginal microbicide and diaphragm use for sexually transmitted infection prevention: a randomized acceptability and feasibility study among high-risk women in Madagascar.

Authors:  Frieda M Behets; Abigail Norris Turner; Kathleen Van Damme; Ny Lovaniaina Rabenja; Noro Ravelomanana; Teresa A Swezey; April J Bell; Daniel R Newman; D'Nyce L Williams; Denise J Jamieson
Journal:  Sex Transm Dis       Date:  2008-09       Impact factor: 2.830

6.  HPTN 035 phase II/IIb randomised safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women.

Authors:  M Bradford Guffey; Barbra Richardson; Marla Husnik; Bonus Makanani; David Chilongozi; Elmer Yu; Gita Ramjee; Nyaradzo Mgodi; Kailazarid Gomez; Sharon L Hillier; Salim Abdool Karim
Journal:  Sex Transm Infect       Date:  2014-06-04       Impact factor: 3.519

7.  Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread.

Authors:  Natalia Cheshenko; Marla J Keller; Veronica MasCasullo; Gary A Jarvis; Hui Cheng; Minnie John; Jin-Hua Li; Kathleen Hogarty; Robert A Anderson; Donald P Waller; Lourens J D Zaneveld; Albert T Profy; Mary E Klotman; Betsy C Herold
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

8.  Phase I randomized safety study of twice daily dosing of acidform vaginal gel: candidate antimicrobial contraceptive.

Authors:  Marla J Keller; Colleen A Carpenter; Yungtai Lo; Mark H Einstein; Congzhou Liu; David N Fredricks; Betsy C Herold
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

9.  Noninvasive routes of proteins and peptides drug delivery.

Authors:  P K Sharma; Sumedha Bansal; Arunabha Banik
Journal:  Indian J Pharm Sci       Date:  2011-07       Impact factor: 0.975

Review 10.  Microbicides: a new hope for HIV prevention.

Authors:  Satish K Gupta
Journal:  Indian J Med Res       Date:  2011-12       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.